IP Library Granted Patent US 11,059,869
Granted Patent B2
US 11,059,869 · App. 14/006,954 · Granted Jul 13, 2021

Compositions for enhancing the pluripotency of stem cells

Inventors: Minoru S. H. Ko (Cockeysville, MD); Tomokazu Amano (Parkville, MD)
Assignees: ELIXIRGEN, LLC; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
C07K14/47C07K14/70567C07K14/721C12N5/0606C12N5/0696C12N15/62C12N15/79C12N15/85C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,059,869
App. No.
14/006,954
Granted
Jul 13, 2021
Kind
B2
Abstract

Described herein is the finding that increasing the frequency of Zscan4 activation in mouse ES cells not only enhances, but also maintains their developmental potency in long-term cell culture. Particularly disclosed herein is the finding that the constitutive presence of Zscan4-ERT2, even in the absence of its usual activator tamoxifen, can increase the frequency of endogenous Zscan4 activation in ES cells, resulting in the increase of developmental potency of the ES cells. Accordingly, provided herein are Zscan4-ERT2 fusion proteins and nucleic acid molecules and vectors encoding Zscan4-ERT2 fusion proteins. Further provided are methods of prolonging and/or enhancing stem cell plmipotency using the disclosed Zscan4-ERT2 nucleic acid molecules and fusion proteins.

Claims (15)

1. An expression vector comprising a nucleic acid molecule encoding a Zscan4-ERT2 fusion protein operably linked to a promoter, wherein the Zscan4-ERT2 fusion protein consists of the amino acid sequence of SEQ ID NO: 22 or SEQ ID NO: 23.

2. An isolated cell comprising the expression vector of claim 1 .

3. The isolated cell of claim 2 , which is a stem cell.

4. The isolated cell of claim 3 , wherein the stem cell is an embryonic stem (ES) cell or an induced pluripotent stem (iPS) cell.

5. The isolated cell of claim 3 , wherein the stem cell is a mouse, rat, human or non-human primate stem cell.

6. A composition comprising the expression vector of claim 1 and a pharmaceutically acceptable carrier.

7. The expression vector of claim 1 , wherein the Zscan4-ERT2 fusion protein consists of the amino acid sequence of SEQ ID NO: 23.

8. The expression vector of claim 1 , wherein the Zscan4-ERT2 fusion protein consists of the amino acid sequence of SEQ ID NO: 22.

9. An expression vector comprising a nucleic acid molecule encoding a mutant Zscan4-AC protein operably linked to a promoter, wherein the mutant Zscan4-AC protein consists of the amino acid residues (i) 1-311 of SEQ ID NO:2, (ii) 1-339 of SEQ ID NO: 2, (iii) 1-367 of SEQ ID NO: 2, (iv) 1-395 of SEQ ID NO: 2, (v) 1-394 of SEQ ID NO: 8, (vi) 1-423 of SEQ ID NO: 8, (vii) 1-451 of SEQ ID NO: 8, or (viii) 1-479 of SEQ ID NO: 8.

10. An isolated cell comprising the expression vector of claim 9 .

11. The isolated cell of claim 10 , which is a stem cell.

12. A composition comprising the expression vector of claim 9 and a pharmaceutically acceptable carrier.

13. The expression vector of claim 9 , wherein the mutant Zscan-ΔC protein consists of the amino acid sequence of SEQ ID NO: 25.

14. The expression vector of claim 9 , wherein the mutant Zscan4-AC protein consists of the amino acid residues (i) 1-311 of SEQ ID NO:2, (ii) 1-339 of SEQ ID NO: 2, (iii) 1-367 of SEQ ID NO: 2, or (iv) 1-395 of SEQ ID NO: 2.

15. The expression vector of claim 9 , wherein the mutant Zscan4-AC protein consists of the amino acid residues (v) 1-394 of SEQ ID NO: 8, (vi) 1-423 of SEQ ID NO: 8, (vii) 1-451 of SEQ ID NO: 8, or (viii) 1-479 of SEQ ID NO: 8.

Assignments (4)
CHANGE OF NAME Recorded Jun 11, 2026
From: ELIXIRGEN, LLC
To: ENGINS, LLC
Reel/Frame 075712/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2014
From: KO, MINORU SHIL HONG
To: ELIXIRGEN, LLC
Reel/Frame 032566/0988 →
NIH WAIVER OF DR. MINORU KO'S RIGHTS Recorded Feb 12, 2014
From: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
To: KO, MINORU, DR.
Reel/Frame 032262/0961 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: KO, MINORU S.H.; AMANO, TOMOKAZU
To: THE UNITED STATES OF AMERICA, SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 032187/0752 →
Continuity (2)
Provisional Application 61466667 · Mar 23, 2011
Related Publication 20140370601A1 · Dec 18, 2014